POST SUMMARY: Consumers don’t trust big pharma, but hey are going online in bigger numbers to get health information. If we want to be part of the conversation we need to EARN their trust one patient at a time. It’s not going to be easy, but we need to fight for patients at every meeting and within every online digital interaction.
POST SUMMARY: There can be no doubt that changes are needed within biopharma DTC marketing to ensure that marketing to patients and consumers remains relevant. However, as long as antiquated hiring practices and rebels are denied entry into DTC marketing the industry is doomed to see budgets cut further as senior management looks to cut costs.
POST SUMMARY: To say that 2014 has been a challenging year for pharma would be an understatement. Budget cuts are kicking in and 86% of Rx’s are now generic medications while sales and marketing budgets have hit a dead end. More than that a lot of very talented and good DTC marketing people have left the industry because job satisfaction is a lot more important than a paycheck.
POST SUMMARY: Google said that AdWords will no longer allow advertisers to prevent their ads from showing up on “close variants” of their keywords — i.e., ads will, by default, show up on both the advertiser’s keywords and on close spellings. If you bid on the singular version of a keyword, it might also show on the plural version and you can no longer tell Google you don’t want that. Your ads might also show on misspellings and other “close variants” of your keywords. In other words you need to purchase spelling variants of your product and disease state for paid search.